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Abstract
Objective. Serum cytokines play an important role in the pathogenesis of myositis by initiating and
perpetuating various cellular and humoral autoimmune processes. The aim of the present study was to
describe a broad spectrum of T- and B-cell cytokines, growth factors and chemokines in patients with
idiopathic inflammatory myopathies (IIMs) and healthy individuals.
Methods. A protein array system, denoted as multiplex cytokine assay was utilized to measure simultan-
eously the levels of 24 circulating cytokines, including B-cell activating factor (BAFF) and a proliferation
inducing ligand (APRIL) of patients with IIMs and healthy individuals. Additionally, correlational clustering
and discriminant function analysis (DFA), two multivariate, supervised analysis methods were employed to
identify a subset of biomarkers in order to describe potential functional interrelationships among these
pathological cytokines.
Results. Univariate analysis demonstrated that a complex set of immune and inflammatory modulating
cytokines are significantly up-regulated in patients with IIMs relative to unaffected controls including IL-10,
IL-13, IFN-a, epidermal growth factor (EGF), VEGF, fibroblast growth factor (FGF), CCL3 [macrophage
inflammatory protein (MIP-1a)], CCL4 (MIP-1b) and CCL11 (eotaxin), whereas G-CSF was significantly
reduced in IIM patients. Correlational clustering was able to discriminate between, and hence sub-classify
patients with IIMs. DFA identified EGF, IFN-a, VEGF, CCL3 (MIP-1a) and IL-12p40, as analytes with the
strongest discriminatory power among various myositis patients and controls.
Conclusions. Our findings suggest that these factors modulate myositis pathology and help to identify
differences between subsets of the disease.
Key words: Idiopathic inflammatory myopathies, Circulating cytokines, B-cell activating factor, A proliferation
inducing ligand.
Introduction
Idiopathic inflammatory myopathies (IIMs) encompass
a heterogeneous group of systemic immune-mediated
connective tissue disorders that include PM, DM, juvenile
dermatomyositis (JDM), overlap myositis (OM), cancer-
associated myositis (CAM) and IBM [1]. IIMs are relatively
rare diseases. Estimates of prevalence range from 0.5 to
9.3 cases/million [1–3].
While these conditions may share certain similarities,
they have distinct clinical, histopathological, immuno-
logical and pathogenic features [1–3]. Although the
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skeletal muscle pathology in IIMs generally consists of
focal inhomogeneous chronic inflammation with albeit
variable endomysial, perimysial or perivascular mononu-
clear infiltration, certain characteristic differences in these
different subtypes reflect their distinct pathophysiological
pathways [4–6]. A cascade of inflammatory mediators, pri-
marily cytokines are key players of these immune re-
sponses. They modulate important distinct biological
cellular functions that trigger downstream signalling path-
ways, and mediate immune cell proliferation and differen-
tiation in IIMs. Differences between PM and DM in the
level of peripheral blood lymphocytes and their intracellu-
lar cytokine content have been reported [7]. Studies on
cytokine gene, RNA and protein expression in muscle
tissue from patients with various forms of the disease in-
dicate similar profiles, despite different phenotypes of the
inflammatory cells present in muscle tissue from the dif-
ferent subsets of myositis. A wide range of cytokines have
been described to be expressed in muscle tissue and
elevated in blood from patients with IIMs, amongst
others the pro-inflammatory cytokines IL-1a, IL-1b,
TNF-a, as well as the inhibitory cytokine TGF-b [8–11].
Many of these pro-inflammatory cytokines induce meta-
bolic effects on myocytes, which are likely to play a role in
the characteristic muscle degeneration observed in these
patients and indicate additional pathogenic pathways for
inducing muscle dysfunction in patients with chronic in-
flammatory myopathies besides muscle fibre necrosis
[12–14]. There is also a characteristically high expression
of MHC class I, and to a somewhat lesser extent MHC
Class II, on muscle fibres associated with myositis indicat-
ing that the muscle cells actively participate in the inflam-
matory process by mediating recognition and invasion by
cytotoxic T cells [8–10].
Several cytokines, including IL-1, TNF-a and IFNs,
which are known to be potent inducers of MHC Class I
expression on muscle fibres [15] have been observed in
muscle tissue of these patients, supporting the assump-
tion that cytokines play a pivotal role in the pathogenesis.
A shared histopathological feature in this heteroge-
neous group of disorders is the presence of inflammatory
infiltrates in muscle tissue, mostly consisting of T cells and
macrophages [16, 17]. The infiltrating cells detected in
affected muscles from patients with IIMs are potent pro-
ducers of pro-inflammatory cytokines. However, inflam-
matory cell infiltrates are not always detectable;
moreover, the presence or absence of inflammatory cell
clusters does not always correlate with the clinical symp-
tom of muscle weakness [1, 9, 10]. Thus, cytokines pro-
duced by cell types other than the inflammatory cells,
such as IL-1a expressed in endothelial cells, could also
play a role in disease mechanism and contribute to the
clinical symptoms.
B-cell activating factor (BAFF) and a proliferation-
inducing ligand (APRIL) are members of the TNF superfam-
ily [18–22]. Despite the similar structure and shared recep-
tor specificity, BAFF and APRIL have distinct functions.
APRIL appears to play a role in T-independent type II anti-
gen responses and T-cell survival, and can also induce
proliferation/survival of non-lymphoid cells [23]. BAFF en-
hances the survival of immature B cells at the T1 and T2
stages of development as well as of mature B-cells in vitro
[24]. Recently, BAFF has also been suggested to be
involved in T-cell responses. BAFF co-stimulates human
T-cell activation in vitro [25, 26]. BAFF, APRIL and their re-
ceptors have been shown to have key functions in both B-
and T-cell homeostasis and could be instrumental in the
pathogenesis of autoimmune diseases. Abnormal levels
of both BAFF and APRIL have been observed in patients
with autoimmune diseases, such as SLE, RA and SS [27–
29]. It follows, therefore, that these molecules represent
exciting new targets of therapeutic intervention in autoim-
mune diseases [30].
The aim of the present study was to identify a broad
spectrum of cytokines, chemokines, growth and angio-
genic factors, as well as BAFF and APRIL, in the periph-
eral blood of patients with IIMs, and utilize multivariate
biostatistical analyses to describe putative regulatory net-
works among these factors. In doing so, we have demon-
strated the presence of disease-perpetuating cytokines
up-regulated in IIMs, sera, mediators with both diagnostic
and mechanistic potential. We have also characterized
likely interplay among these cytokines using multivariate
analysis methods that model network-like behaviour
among biological variables. Finally, we have followed up
the cytokine profile of a patient with JDM before and after
various treatment modalities by utilizing univariate and
multivariate analyses and pinpointed key cytokines, clear-
ly reflecting the disease improvement, therefore being ex-
cellent candidates for therapeutic efficacy indicators.
Materials and methods
Patients
Seventy-two Caucasian patients (55 females and
17 males) with IIM, who were diagnosed, treated and fol-
lowed up at the Division of Clinical Immunology, 3rd
Department of Internal Medicine, Medical and Health
Science Center, University of Debrecen, and the
2nd Department of Pediatrics, Semmelweis University,
Budapest, Hungary participated in this study. The mean
age of the patients was 39.42 years (range: 5.99–81.88).
The cohort included 21 patients with PM, 26 patients with
DM, 9 patients with JDM, 9 patients with CAM and 7 pa-
tients with OM. In the OM group, the associated autoim-
mune diagnoses included RA (three patients), SSc
(two patients), polychondritis (PC; one patient) and SS
(one patient). All patients fulfilled the Bohan and Peter
criteria for definite IIM [31] and the diagnosis of OM was
defined by the presence of Bohan and Peter criteria for
myositis, as well as the criteria for the corresponding CTD
[32–36]. All patients in the study had active disease. To
control for the influence of treatment, while low-dose cor-
ticosteroids were allowed, patients on immunosuppres-
sive drugs, or biologics were excluded from the study.
The cohort also included 25 age- and sex-matched
healthy Caucasian controls, all of whom were healthy
blood donors, without any sign of myositis, arthritis,
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ongoing inflammation or autoimmune conditions. Controls
were medication free at least 3 months before this study.
General laboratory and immuno-laboratory assessments
included ESR/Westergren (ESR/We), CRP, white blood
cell (WBC) count, haemoglobin (Hb) and a broad spectrum
of imunoserological investigations, including IgG, IgA,
IgM, complement (C)3, C4, IC, complement activity
(CH50), cryoglobulin, ANA, RF, anti-dsDNA, anti-Sm,
anti-Sm/RNP, ENA, anti-SS-A, anti-SS-B, anti-Scl-70,
anti-Jo-1, aCL, anti-b2glycoprotein I (B2GPI)-IgG/IgA/
IgM, ACA, ASM, anti-liver–kidney microsomal (LKM), par-
ietal cell antibodies, AMA, ANCAs, anti-cyclic citrullinated
peptide (CCP), AECAs, thyroglobulin antibodies (TGs),
anti-thyroid peroxidase (TPO). In JDM, the provisional
Paediatric Rheumatology International Trials
Organization ACR/EULAR criteria for the evaluation of re-
sponse to therapy were used to assess clinical response
[37]. Health assessment questionnaire (HAQ), myositis
disease activity assessment tool (MDAAT), manual
muscle strength testing (MMT), along with muscle-
associated enzymes [creatine kinase (CK), LDH] were as-
sessed in IIM patients. In adults, functional outcome and
quality of life was measured by the Health Assessment
Questionnaire Disability Index (HAQDI) and Short Form
36-item questionnaire (SF-36) [38]. The protocol was in
full compliance with Good Clinical Practices, the
Declaration of Helsinki and the guidelines of the Medical
and Health Science Centre of the University of Debrecen.
The study has been approved by the institutional ethics
committee (Regional and Institutional Ethics Committee,
Medical and Health Science Centre, University of
Debrecen). Written informed consent was obtained from
all patients for publication of the study.
Serum samples
Blood samples were obtained from both patients and un-
affected controls after informed consent and treated an-
onymously throughout the analysis. Blood was collected
in endotoxin-free silicone-coated tubes without additive.
The blood samples were allowed to clot at room tempera-
ture for 30 min before centrifugation (1800 RCF, 4C,
10 min) and the serum was removed and stored at
80C until analysed.
Multiplex cytokine assay
Serum levels of cytokines and chemokines, including
IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, CXCL8 (IL-8), IL-10,
IL-12 (p40), IL-13, IL-15, IL-17, IFN-a and IFN-g, TNF-a,
GM-CSF, IFN-induced-protein-10 (IP-10), CCL2 [mono-
cyte chemoattractant protein-1 (MCP-1)/(MCAF)], CCL3
[macrophage inflammatory protein 1-a (MIP-1a)], CCL4
[macrophage inflammatory protein 1b (MIP-1b)], CCL11
(eotaxin) and IL-1 receptor a (IL-1Ra) were measured
using a bead-based immunofluorescence assay
(Luminex, Austin, TX, USA) using multiplex cytokine re-
agents supplied by Biosource International, Camarillo,
CA, USA, as previously described [39, 40]. Briefly, a
sandwich immunoassay-based protein array system
(Biosource), which contains dyed microspheres
conjugated with a monoclonal antibody specific for a
target protein was used in this assay. Serum samples
were thawed and run in duplicate. Antibody-coupled
beads were incubated with the plasma sample (antigen)
after which they were incubated with biotinylated detec-
tion antibody before finally being incubated with strepta-
vidin–phycoerythrin. A broad sensitivity range of
standards (Biosource), ranging between 1.95 and
32 000 pg/ml were used to help enable the quantitation
of a dynamic wide range of cytokine concentrations and
provide the greatest sensitivity. These captured bead
complexes were then read by the Bio-Plex array reader
(Bio-Rad Laboratories, Hercules, CA, USA), which uses
Luminex fluorescent-bead-based technology (Luminex)
with a flow-based dual laser detector with real-time digital
signal processing to facilitate the analysis of up to
100 different families of colour-coded polystyrene beads
and allow multiple measurements of the sample ensuing
in the effective quantification of cytokines.
Validation of the multiplex assays was performed
using single protein ELISAs (Biosource). Values obtained
from multiplex assay analytes were highly correlative
[(Spearman’s rank correlation coefficient, 0.97 (0.03)],
when compared with individual ELISAs for particular cyto-
kines. Although it has been demonstrated that the myo-
cytic cellular and molecular cytokine expression levels of
inflammatory myopathy patients are much higher than in
healthy individuals [8, 10, 11], our understanding of the
role of these cytokines is largely limited to analyses of
individual cytokines. It therefore has made it imperative
for us to study the intricacy of the dynamic cytokine net-
work and its dependency upon the complex interplay of
multiple signalling molecules or pathways. We therefore
compared the serum levels of 24 cytokines/chemokines in
a multiplex platform between myositis patients and un-
affected control individuals and between various subsets
of patients with IIMs. The cytokines assayed included
modulators of several key aspects of disease pathology
including regulation of inflammation, cellular and humoral
immunity, leucocyte trafficking, cell growth and angiogen-
esis. To facilitate functional interpretation of results, cyto-
kines were sorted into four functional groups in the
graphical representations of these analyses.
ELISA for sBAFF and sAPRIL
Serum samples were thawed and immediately analysed
by a commercial human sBAFF ELISA kit (Quantikine
Human BAFF/BlyS/TNFSF13B Immunoassay; R&D
Systems, Minneapolis, MN, USA) and a commercial
human sAPRIL ELISA kit (Bender MedSystems GmbH,
Vienna, Austria) according to the manufacturers’ instruc-
tions. Results are presented in picograms/millilitre for
sBAFF and nanograms/millilitre for sAPRIL.
Statistical analysis
Cytokine concentrations were obtained through a five par-
ameter logistic regression of a standard curve [41].
Cytokines in this assay are distributed log normally; there-
fore, all concentrations were transformed by Log2(X+ 1)
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before further analysis. Statistical differences in measured
values were assessed by a Mann–Whitney U-test.
P< 0.05 was considered statistically significant. To evalu-
ate how well an arbitrary monotonic function could de-
scribe the relationship between two variables, a non-
parametric measure of correlation between variables
defined by Spearman’s correlational coefficient (r) was as-
sessed (ranging from negative correlation of 1.00 to a
positive correlation of +1.00), and a t-test was used to
establish whether the correlation coefficient is significant.
We also used hierarchical clustering analysis to cluster
the correlational profiles into meaningful structures, as
per Eisen et al. [42]. The analysis clusters the variables
(biomarkers) according to the similarity or dissimilarity of
their profiles, placing the variables with similar relationship
together as neighbouring rows, which was then depicted
graphically in a dendrogram, in which the correlation
determined the branch length of the dendogram.
Principal component analysis
Principal component analysis (PCA) is a common
dimension reduction technique that creates linear combin-
ations of variables that are uncorrelated. These uncorre-
lated ‘principal components’ (PCs) can be used in
multivariate analysis [43]. PCA was performed as a way
of identifying patterns within the variables, and expressing
them in such a way as to highlight their similarities and
differences. A PCA with Varimax rotation was used to
uncorrelate the cytokines. It is important to note that
some cytokine values in the resulting data set were
below the limit of detection. In this case, a cold-deck im-
putation of the lowest quantifiable standard was used [44].
This estimate uses our knowledge that the cytokine values
are at most the values that were imputed. If any cytokine
required >20% imputation the cytokine was dropped from
further analysis. The dataset was then randomly split into
two datasets: a test and a training dataset. One hundred
individuals, 50 myositis and 50 controls, comprised the
training set, while 49 subjects, 29 myositis and 20 controls,
comprised the test set. The training dataset will be used to
construct our predictive model, whereas the test dataset
provides independent validation of our model. An eigen-
value >1 was used to retain PCs. Once new variables had
been created the resulting components were placed into a
logistic regression to create a predictive model of myositis.
An a< 0.05 was considered statistically significant. The
SAS system v 9.1.3 (Statistical Analysis System, Cary,
NC, USA) was used for statistical analysis.
Discriminant function analysis
Discriminant function analysis (DFA) is a multivariate class
distinction algorithm that allows one to construct a math-
ematical model of discrimination built in a stepwise
manner. This analysis was used here to identify the cyto-
kines that best discriminated between patients with IIMs
and controls, and was modelled as previously described
[39, 45]. Specifically, at each step, all variables are re-
viewed to determine which will maximally discriminate
between groups. These variables are then included in a
discriminative function, denoted a root, which is an equa-
tion consisting of a linear combination of cytokine
changes used for the prediction of group membership.
Variables will continue to be included in the model as
long as the respective F-values for those variables are
larger than the standard threshold (established by the
analytical package Statistica; StatSoft, Tulsa, OK, USA).
The discriminant potential of the final equation from the
forward stepwise DFA can then be observed in a simple
multidimensional plot of the values of the roots obtained
for each group. This multivariate approach identifies
groups of analytes, the changes of which in levels can
delineate profiles and create diagnostic patterns.
Results
Unique systemic immune profiles identified in IIMs
Measured biomarkers were catalogued in four functional
subsets. This included a group denoted cellular cytokines
that drive, albeit not exclusively, cytotoxic and anti-viral
responses (e.g. IL-1b, IL-1Ra, IL-2, IL-7, IL-12, IL-15,
IL-17, TNF-a, IFN-a, IFN-g; Fig. 1A), ‘humoral cytokines’
(e.g. IL-4, IL-5, IL-6, IL-10, IL-13; Fig. 1B), ‘growth factors’
(e.g. GM-CSF) and ‘chemokines’ [e.g. CCL2 (MCP-1),
CCL3 (MIP-1a), CCL4 (MIP-1b), CCL11 (eotaxin)],
CXCL8 (IL-8) and CXCL10 (IFN-g-inducible protein of
10 kDa; IP-10; CXCL10; Fig. 1C). DM patients demon-
strated a unique profile with significant (P< 0.05) elevated
levels of cellular, cytotoxic cytokines (IL-1b, IL-7, IL-12,
IL-17, IFN-a), humoral (IL-6 and IL-10) and a profound
chemotactic profile [CCL2 (MCP-1), CCL3 (MIP-1a),
CCL4 (MIP-1b), CCL11 (Eotaxin)], CXCL8 (IL-8) and
CXCL10 (IP-10; Fig. 1). PM patients demonstrated a less
predominant immune profile (when compared with DM)
with a bias towards cellular cytokines and chemokines
with significant (P< 0.05) elevations of IL-17, GM-CSF,
IFN-a, IL-1Ra, IL-7, CCL11, CCL3 and CCL4 (Fig. 1).
When compared with DM and PM, patients with JDM
demonstrated a Th1-predominant profile with significant
(P< 0.05) elevations of IL-1b, IL-12, GM-CSF, IFN-a and
IL-1Ra, and a chemotactic profile (CCL11, CCL3, CCL4
and CXCL10) (Fig. 1). It is important to note that Th17
mediators were not elevated in JDM, and that IL-15 was
significantly decreased in JDM when compared with con-
trols and other conditions. In CAM, both Th1 and Th17
were involved along with chemokines, but rather with a
unique profile with significant (P< 0.05) elevations of
IL-1b, IL-17, GM-CSF, IFN-a, IL-1Ra, CCL11, CCL3,
CCL4 and CXCL10 (Fig. 1). Also of importance is that
IL-10 was the only humoral cytokine that was significantly
(P< 0.05) elevated in PM, JDM and CAM (Fig. 1B). As
shown in Fig. 1, patients with overlap diseases had a
mixed-diverse cytokine profile with significant elevation
(P< 0.05) of Th1, Th2 and chemokines (IL-1b, IL-12,
GM-CSF, IL-1Ra, IL-7, IL-6, IL-10, IL-13, CCL3, CCL4
and CXCL10). While these patterns represent the first
ever, unique immunomodulatory multiplex profiles
identified in IIMs, the complex dynamic nature of the
immune profiles in IIMs warrants the necessity to perform
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multivariate analysis to identify discriminatory patterns
in IIMs.
Correlational and cluster analysis identifies cytokine
profiles that closely associate with BAFF and APRIL
Given the potential role of BAFF/APRIL as immunomodu-
lators in the pathogenesis of autoimmune diseases, we
compared and correlated the systemic levels of BAFF/
APRIL with that of systemic cytokines and chemokines in
IIM. Correlation was assessed by Spearman’s correlation
analysis, which allows for effective evaluation of the rela-
tionship between two variables (BAFF/APRIL and respect-
ive cytokines/chemokines). As depicted in Fig. 2A, in IIM,
BAFF was highly correlated with IL-12 (r= 0.457,
P< 0.0001), and moderately correlated with ESR
(r= 0.307, P= 0.009), IL-1Ra (r= 0.294, P= 0.012),
CXCL10 (r= 0.279, P= 0.017), IL-7 (r= 0.269, P= 0.022).
On the other hand, in IIM, APRIL was correlated with IL-6
(r= 0.263, P= 0.026), CXCL10 (r= 0.243, P= 0.039) and RF
(r= 0.237, P= 0.045; Fig. 2B). To assess the similarities or
differences of cytokine changes among the groups stu-
died, hierarchical clustering analysis was also applied to
the dataset of IIM. This helped construct a series of nested
clusters of data based on the proximity information and
interplay between variables (including BAFF, APRIL and
cytokines) associated with an observation. Clear separ-
ation of variables was apparent, in which BAFF, APRIL,
CXCL10, CCL2, CCL3, CCL4 and IL-1Ra depicted a tight
cluster, when compared with other variables (Fig. 2C).
PCAs enable effective evaluation of immune profiles
in patients with IIM and identify components of
cytokine profiles as prognostic tools in a case of
active JDM
Most multivariate methods of data analysis require that
variables be independent or at least uncorrelated. Since
FIG. 1 Distinct cellular cytotoxic, humoral and chemotactic patterns identified in IIMs. Levels of 24 serum biomarkers
were measured simultaneously using a biometric multiplex assay from serum of subsets of patients with IIMs, and
unaffected control individuals. (A) Cellular cytotoxic patterns identified elevations of IL-1b, IL-7, IL-12, IL-17, IFN-a in DM,
IL-17, GM-CSF, IFN-a, IL-1Ra, IL-7 in PM, IL-1b, IL-12, GM-CSF, IFN-a and IL-1Ra in JDM, and IL-1b, IL-17, GM-CSF,
IFN-a, IL-1Ra in CAM. (B) Humoral patterns identified elevations of IL-6 and IL-10 in DM, and IL-10 in PM, JDM and CAM.
(C) Chemotactic patterns identified elevations of CCL2, CCL3, CCL4, CCL11, CXCL8 and CXCL10 in DM, CCL11, CCL3
and CCL4 in PM, CCL11, CCL3, CCL4 and CXCL10 in JDM, and CCL11, CCL3, CCL4 and CXCL10 in CAM. Patients with
overlap diseases had a mixed-diverse cytokine profile with significant elevations of IL-1b, IL-12, GM-CSF, IL-1Ra, IL-7,
IL-6, IL-10, IL-13, CCL3, CCL4 and CXCL10. Cytokines significantly elevated in groups relative to controls are denoted
with an asterisk (*P< 0.05 and **P< 0.001).
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cytokines function in an intricate network, they are highly
dependent upon one another and do not meet this re-
quirement. PCA reduces dimensionality by rejecting low
variance, and is therefore helpful to measure separation
between the samples in the estimated feature space. PCA
effectively enables the identification of more informative
uncorrelated novel features, increasing the ability to inter-
pret and analyse the profiles. After imputation, 16 of
22 cytokines were eligible for further analysis. These in-
clude: IL-1b, IL-2, IL-6, IL-7, IL-8, IL-10, IL-12, IL-15,
TNF-a, GM-CSF, CCL2, CCL3, CCL4, CXCL10 and
IL-1Ra. These data were split into test and training data-
sets. PCA was performed on the training set and resulted
in three PCs being retained that explained 89% of the
variability in the dataset (Table 1). All three PCs were mod-
elled in a logistic regression. Only PCs 2 and 3 were stat-
istically significant (data not shown).
The cytokines causing the most variability were IL-10
and GM-CSF in PC2 and CXCL10 and CCL2 in PC3
(Table 2). A key advantage of the PCA analysis was that
PCA reduces data complexity in a rational way without
any prior knowledge of categories so as to determine
whether any intrinsic clustering or outliers existed within
the data set. The test data applied to this model had an
area under the curve of 0.75, indicating the remarkable
discriminatory power of the model (Fig. 3A).
In order to assess the prognostic power of the model
identified by the PCA, we investigated the role of PC2 and
PC3 modulatory cytokines in the therapeutic response of
a patient with active JDM (based on diagnostic criteria).
This patient was treated with i.v. methylprednisolone
(250 mg for 3 days, 125 mg for 3 days, then tapered to
80 mg/day), ciclosporin (2 x 100 mg/day), MTX (12.5 mg/
week) and i.v. immunoglobulin (1 g/kg for 3 days) and
was prospectively followed from baseline through a total
of six visits in 2 weeks. Multiplex serum cytokines were
used to identify the potential of the predictive model iden-
tified by the PCA in a prospective manner (Fig. 3B). To
obtain results that could be readily interpreted in a clinical
context, a cytokine activity score (CAS) was created using
data that were rescaled so that a value of 0 characterizes
the value of the healthy controls. This value was plotted
over time during treatment to assess patient response. In
this form of a preliminary assessment, our results clearly
demonstrate that changes in the CAS for PC3 correlated
well with clinical response and that PC3 cytokine values
obtained within as early as 2 weeks of therapy can reflect
response (Fig. 3B). This pharmacoproteomic analysis
utilizing a CAS provides a means of developing a clinical
assay that monitors a patient’s response to therapy, and
therefore indicates its potential as a vital tool in the
management of IIM.
Discriminative cytokine profiles identify novel
disease-specific patterns in IIMs
Complementary multivariate analytical methods provide a
vivid picture of the biological significance of the immune
profile network. A DFA is distinct from the above analyses
in that it is a class distinction modelling method that iden-
tifies sets of variables that best discriminate predefined
IIM groups. The utility of this analysis is that it identifies
groups of analytes, the changes of which in levels can
delineate profiles and create diagnostic patterns in IIM.
Results of DFA can be visualized on a multidimensional
plot, with class discrimination power represented by dis-
tance between IIMs. All disease states were readily dis-
tinguished from controls (Fig. 4). Interestingly, subsets of
IIM clustered into significantly independent positions on a
3-dimensional (3D) plot, distinctly further away from
TABLE 1 Eigenvalues from PCA
Principal
component Eigenvalue
Proportion
variance
explained
Cumulative
variance
explained
1 6.080 0.5867 0.5867
2 1.834 0.177 0.7637
3 1.286 0.1241 0.8878
4 0.726 0.07 0.9578
5 0.436 0.0421 0.9999
6 0.356 0.0344 1.0343
7 0.271 0.0261 1.0604
8 0.098 0.0095 1.0699
9 0.030 0.0029 1.0728
10 0.002 0.0002 1.0729
11 0.028 0.0027 1.0702
12 0.077 0.0075 1.0628
13 0.086 0.0083 1.0545
14 0.152 0.0147 1.0398
15 0.177 0.0171 1.0227
16 0.236 1
The PC factors with eigenvalues that can be retained based
on the Kaiser criterion are shown in bold.
TABLE 2 Rotated PC pattern
Cytokine PC1 PC2 PC3
IL-1b 0.73 188 0.36 032 0.02 632
IL-2 0.88 887 0.28 073 0.02 907
IL-6 0.48 319 0.56 195 0.269
IL-7 0.40 635 0.4299 0.02 552
IL-8 0.1802 0.19 226 0.34 265
IL-10 0.18 827 0.92 429 0.01 971
IL-12 0.39 969 0.0187 0.11 124
IL-15 0.85 637 0.26 156 0.15 085
TNF-a 0.59 444 0.10 031 0.17 035
GM-CSF 0.19 389 0.92 357 0.05 055
CCL3 (MIP-1a) 0.76 841 0.16 808 0.16 933
CCL4 (MIP-1b) 0.67 661 0.20 326 0.06 701
IP-10 0.00 195 0.09 039 0.74 197
CCL11 (eotaxin) 0.02 096 0.05 098 0.52 972
CCL2 (MCP-1) 0.22 375 0.11 251 0.83 513
IL-1Ra 0.67 532 0.12 795 0.32536
The cytokines causing the most variability in PC1, PC2 and
PC3 are shown in bold.
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controls. Moreover, representative of their relative disease
activity, patients with JDM mapped closer to patients with
DM, suggesting that this is directly proportional to inter-
group cytokine variation and intragroup heterogeneity
in cytokine profiles and disease pathology (Fig. 4).
Additionally, OM was distributed all over without any spe-
cific distinctive location, indicative of the nature of the
pathogenesis of its disease (data not shown). Of the vari-
ables analysed, IL-1b, IL-10, IL-12, GM-CSF, CCL4 and
CXCL10 were identified by DFA as having the highest
power for class discrimination between the groups.
When compared with Fig. 1, which demonstrates the
levels of each of these cytokines, it can be noted that
these cytokines distinctly vary among the different dis-
ease subgroups, and as such indicates its discriminatory
potential. This suggests that these biomarkers play a
significant role in pathology within this cohort.
Discussion
Specific targeted therapies involving modification of
cytokines could improve the health of patients, while
increasing our knowledge of the involvement of
particular cytokines in myositis. Although few such
targeted therapies have been put into practice treating
myositis to date, the future of this type of therapy seems
very promising. This study demonstrates the significant
diagnostic potential for the classification of IIMs vs healthy
controls using multivariate analysis of 24 serum
biomarkers.
The poorly demonstrated relationship between infiltrat-
ing cells, clinical observations and target tissue cytokine
expression implies that all IIM varieties may share a similar
pathogenic pathway. Unfortunately, the effects of most
cytokines on myositis require further study. However, it
is known that the myocytic cellular and molecular cyto-
kines of inflammatory myopathy patients are expressed at
considerably higher levels than in healthy individuals.
When the novel TNF-superfamily members BAFF and
APRIL were evaluated, we found that both ligands were
significantly increased in patients with IIMs, yet in sub-
group analysis we did not see differences in BAFF
levels, only between APRIL in healthy individuals, vs DM
and CAM. Interestingly, positive correlation was found
between BAFF and IL-1Ra, IL-7, IL-12, CXCL10, as
well as ESR values, also between APRIL and IL-6,
CXCL10, as well as RF values. Moreover, a clear separ-
ation of variables was apparent, in which BAFF, APRIL,
CCL2, CCL3, CCL4, IL-1Ra, IL-12, CXCL8 and CXCL10
depicted a tight cluster, when compared with other
variables. These findings suggest that both BAFF and
APRIL have a role in the perpetuation of the immune
responses in IIMs; presumably, besides the previously
well-known cellular and humoral immune regulatory func-
tions, they participate in the orchestration of chemokine
secretion and cell-trafficking as well. Based on our results
we suggest that targeting these molecules could be a
FIG. 3 PCA identifies diagnostic and prognostic potential of the modelling cytokine profiles in idiopathic inflammatory
myopathies. PCA increases the ability to identify uncorrelated features and interpret and analyse the profiles by reducing
dimensionality. (A) PCA was performed on the training set and the test data applied to this model had an area under the
curve of 0.75, indicating the remarkable discriminatory power of the model. (B) In order to assess the prognostic power of
the model identified by the PCA, we investigated the role of PCA modulatory cytokines in the therapeutic response of a
patient with active JDM. The data, which were rescaled so that the value of 0 characterizes the level of healthy controls to
create a cytokine activity score, were plotted over time during treatment to assess patient response. Changes for PC3
correlated well with clinical response as early as 2 weeks of therapy, and therefore indicate the prognostic potential of the
model in IIM.
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beneficial approach in the future therapeutic management
of the disease.
We have identified that for all IIMs, IL-1Ra, IFN-a, GM-
CSF, IL-10 and from the chemokines, CCL3 and CCL4,
were the key biomarkers distinguishing them from healthy
individuals. Specific dendritic cell (DC) subsets, plasma-
cytoid DCs, considered the main source of IFN-a, have
been described previously in IIMs [46]. This set of
IIM-specific markers indicates that the intricate interplay
of a broad spectrum of cellular and humoral cytokines, as
well as specific chemokines drive the autoimmune ma-
chinery in these patients.
In further sub-categorization, these biomarkers ap-
peared relevant as well. Moreover, when subsequently
classified various IIMs based on their peripheral biomarker
set-up we characterized and differentiated DM by the
aforementioned, as well as IL-1b, IL-6, IL-7, IL-12, IL-17;
PM by IL-7 and IL-17; JDM by IL-12 and IL-15; CAM by
IL-1b and IL-17; OM by IL-6 and IL-13. DFA-specific vari-
ables to discriminate groups were IL-1b, IL-10, IL-17,
GM-CSF, CCL3 and CCL4.
The shared clinical and molecular characteristics
of IIMs, which include increased cytokine/chemokine
expression—which is correlated with increased muscle
fatigue and degeneration—imply that there is a similar
pathophysiological inflammatory mechanism shared by
this related but varied group of conditions. Many of
these pro-inflammatory cytokines induce metabolic af-
fects on myocytes, which are likely to play a role in the
characteristic muscle degeneration observed in these pa-
tients. Moreover, these results clearly indicate that specif-
ic chemokines are highly involved in the pathogenesis of
IIMs. The up-regulation of these b chemokines may con-
tribute to the initiation and perpetuation of chronic
inflammation and to the focal inflammatory exudates in
the disease [47].
Of the investigated cytokines, IL-17 seemed to be
a solid biomarker, characteristic of almost all IIM
subsets. IL-17 has long been implicated in several auto-
immune diseases, has the ability to induce nuclear
factor-kB (NF-kB) and is a potent inducer of other inflam-
matory mediators [48]. Microarray studies on IL-17-
induced genes revealed that several chemokines such
as CXCL1, CXCL10, CCL2, CCL7, CCL20, as well as
MMP3 and MMP13, were up-regulated upon IL-17 treat-
ment [49]. These findings further reinforce the pivotal
role of IL-17 in the maintenance of tissue inflammation
in IIMs.
In patients with IIMs, one of the novel TNF-family mem-
bers, BAFF, was highly correlated with IL-12 IL-1Ra,
CXCL10 and IL-7, while APRIL was correlated with IL-6
and CXCL10 as well as the general marker of humoral
autoimmune processes, RF. These findings raise the
possibility that both BAFF and APRIL work in a synergis-
tic manner with various pro-inflammatory cytokines
and chemokines, among which IFN-related biomarkers
are of key importance. Recently BAFF has been described
to be elevated in subsets of patients with myositis
and appeared to show positive correlation with CK
levels [50].
Broad-based proteomic screening methods are begin-
ning to reveal the rich repertoire of cytokines at play in a
given form of autoimmune disease. Moreover, our group
has developed increasingly sophisticated multi-variant
analysis methods to aid in our understanding of the
complex regulatory networks of these disease mediators
[39, 40, 45, 51].
The limitation of this study was that the roles of different
doses of corticosteroids and other immunosuppressive
agents, disease duration and disease activity were
not addressed when multivariate analyses were per-
formed, which could be important confounders in the
analysis.
In conclusion, by using these analyses, we have identi-
fied key cytokines, chemokines and growth factors that
seem to perpetuate autoimmune processes in patients
with IIMs, also, can distinguish between various IIM sub-
sets, furthermore enable us to use them as biomarkers, as
well as potential novel therapeutical targets in the future
management of IIMs.
FIG. 4 Novel disease-specific patterns in IIMs. DFA was
used to identify subset of cytokines whose expression
values can be linearly combined in an equation, denoted a
root, whose overall value is distinct for a given charac-
terized group. Results of DFA are visualized here on a
multidimensional plot, with class discrimination power
represented by distance among groups. The variables
identified by the DFA will continue to be included in the
model, as long as the respective F-values for those vari-
ables are larger than the standard threshold and is then
plotted in three dimensions to visually represent the rela-
tive differences in cytokines among the distinct popula-
tions. Using this form of multivariate analysis, subsets of
IIM clustered into unique positions on a 3D plot, distinctly
further away from controls, suggesting the diagnostic
potential of DFA in IIM.
www.rheumatology.oxfordjournals.org 1875
Systemic cytokine profiles in myositis
Rheumatology key messages
. Multiplex cytokine assay and multivariate analyses
aid in patient profiling.
. A broad spectrum of biomarkers signifies various
IIM subsets.
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